Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Patients with chronic limb-threatening ischemia require timely revascularization, but whether clinical outcomes are better with surgical bypass or endovascular therapy is unclear. New research findings are summarized in a short video.

NEJM's profile picture

NEJM

1,002,114 subscribers

88,900 görüntüleme • 3 yıl önce •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

1 Yorum

NEJM profil fotoğrafı
NEJM1 yıl önce

A 𝐦𝐚𝐜𝐫𝐨𝐩𝐡𝐚𝐠𝐞 is a type of immune cell that plays a crucial role in the immune system by digesting cellular debris and pathogens. Macrophages originate from monocytes in the blood and confer innate immunity, which is typically the body’s first line of defense against foreign antigens. In addition, they mediate wound healing and tissue repair by releasing growth factors and antiinflammatory cytokines. Macrophages can be found within many organs, including the liver, brain, bones, and lungs, as well as in the blood, particularly at sites of infection.  To learn more about this NEJM Illustrated Glossary term, read the editorial “Defanging the Neutrophil to Treat Bronchiectasis”: Explore more terms:

Benzer Videolar

Patients with sepsis-induced hypotension are commonly treated with intravenous fluids and vasopressors, but data are limited to guide prioritization of one approach over the other. New research findings are summarized in a short video.
2:04

Patients with sepsis-induced hypotension are commonly treated with intravenous fluids and vasopressors, but data are limited to guide prioritization of one approach over the other. New research findings are summarized in a short video.

NEJM

89,816 görüntüleme • 3 yıl önce

Observational evidence is conflicting on whether the sex of blood donors affects recipient outcomes. New findings from a randomized trial are summarized in this short video.
1:51

Observational evidence is conflicting on whether the sex of blood donors affects recipient outcomes. New findings from a randomized trial are summarized in this short video.

NEJM

42,725 görüntüleme • 3 yıl önce

Coffee is one of the most commonly consumed beverages in the world, but its acute health effects are uncertain. In particular, whether coffee has proarrhythmic effects is a matter of debate. New research findings are summarized in a short video.
1:52

Coffee is one of the most commonly consumed beverages in the world, but its acute health effects are uncertain. In particular, whether coffee has proarrhythmic effects is a matter of debate. New research findings are summarized in a short video.

NEJM

109,634 görüntüleme • 3 yıl önce

An interim analysis of a phase 1–2 study of gene therapy for Artemis-deficient severe combined immunodeficiency suggests that this treatment is safe and effective. New research findings are summarized in a short video.
2:19

An interim analysis of a phase 1–2 study of gene therapy for Artemis-deficient severe combined immunodeficiency suggests that this treatment is safe and effective. New research findings are summarized in a short video.

NEJM

45,461 görüntüleme • 3 yıl önce

Patients with giant-cell arteritis need better treatments. This video, in partnership with Dr. Glaucomflecken, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free:
1:28

Patients with giant-cell arteritis need better treatments. This video, in partnership with Dr. Glaucomflecken, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free:

NEJM

92,855 görüntüleme • 1 yıl önce

Our latest video in our partnership with Dr. Glaucomflecken summarizes new research into therapy for atrial fibrillation in patients with drug-eluting stents. Read the full study for free: nej.md/DrG36 #AFib
1:58

Our latest video in our partnership with Dr. Glaucomflecken summarizes new research into therapy for atrial fibrillation in patients with drug-eluting stents. Read the full study for free: nej.md/DrG36 #AFib

NEJM

13,414 görüntüleme • 4 ay önce

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:
1:29

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:

NEJM

12,252 görüntüleme • 5 ay önce

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:
1:28

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM

16,994 görüntüleme • 6 gün önce

The novel system is a promising option for patients with chronic or complex wounds who require negative pressure wound therapy. Credit: Ghost Medical Marketing & Training Solutions #MedTwitter
2:16

The novel system is a promising option for patients with chronic or complex wounds who require negative pressure wound therapy. Credit: Ghost Medical Marketing & Training Solutions #MedTwitter

The Innovation | Medicine

14,649 görüntüleme • 3 yıl önce

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.
1:30

Our latest video in our partnership with Dr. Glaucomflecken explains the results of the RESHAPE-HF2 trial investigating whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation.

NEJM

98,941 görüntüleme • 1 yıl önce

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:
1:30

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction”:

NEJM

32,419 görüntüleme • 8 ay önce

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:
1:06

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,312 görüntüleme • 3 ay önce

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:
1:20

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:

NEJM

16,263 görüntüleme • 8 ay önce

Management of hospitalized patients with viral pneumonia: NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains recent research into routine antibiotics for hospitalized patients with community-acquired pneumonia and a positive respiratory viral assay. Full context and comment by Dr. Aaron J. Calderon: Visit for the Insights You Need in the Time You Have, including: • Anemia in Chronic Kidney Disease: A New Guideline from KDIGO • People Are Misinformed about Alcohol’s Cancer Risk • Should We Replete Marginally Low Magnesium Levels? • The Public’s Knowledge about Hypertension
1:35

Management of hospitalized patients with viral pneumonia: NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains recent research into routine antibiotics for hospitalized patients with community-acquired pneumonia and a positive respiratory viral assay. Full context and comment by Dr. Aaron J. Calderon: Visit for the Insights You Need in the Time You Have, including: • Anemia in Chronic Kidney Disease: A New Guideline from KDIGO • People Are Misinformed about Alcohol’s Cancer Risk • Should We Replete Marginally Low Magnesium Levels? • The Public’s Knowledge about Hypertension

NEJM

18,584 görüntüleme • 6 ay önce

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:
1:32

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:

NEJM

15,827 görüntüleme • 1 ay önce

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:
1:46

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,795 görüntüleme • 1 yıl önce

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib
1:28

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

NEJM

15,621 görüntüleme • 4 ay önce

Plague is a high-consequence infectious disease with epidemic potential. The latest video in our partnership with Dr. Glaucomflecken summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉
1:24

Plague is a high-consequence infectious disease with epidemic potential. The latest video in our partnership with Dr. Glaucomflecken summarizes new research evaluating ciprofloxacin versus aminoglycoside–ciprofloxacin for bubonic plague in Madagascar. 👉

NEJM

44,943 görüntüleme • 10 ay önce

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:
1:14

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:

NEJM

12,637 görüntüleme • 22 gün önce